Ferras Alwan

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Emicizumab in Acquired Haemophilia A: A Single Haemophilia Comprehensive Care Centre Experience in the United Kingdom.

Emicizumab in Acquired Haemophilia A: A Single Haemophilia Comprehensive Care Centre Experience in the United Kingdom.

Journal: Seminars in thrombosis and hemostasis

Published: April 14, 2026

Autoantibodies enhance ADAMTS-13 clearance in patients with immune thrombotic thrombocytopenic purpura.

Autoantibodies enhance ADAMTS-13 clearance in patients with immune thrombotic thrombocytopenic purpura.

Journal: Journal of thrombosis and haemostasis : JTH

Published: September 30, 2022

Assessing thrombogenesis and treatment response in congenital thrombotic thrombocytopenic purpura.

Assessing thrombogenesis and treatment response in congenital thrombotic thrombocytopenic purpura.

Journal: EJHaem

Published: February 07, 2021

Plasma exchange for COVID-19 thrombo-inflammatory disease.

Plasma exchange for COVID-19 thrombo-inflammatory disease.

Journal: EJHaem

Published: November 05, 2020

Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura.

Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura.

Journal: British journal of haematology

Published: July 28, 2020

Characterization and treatment of congenital thrombotic thrombocytopenic purpura.

Characterization and treatment of congenital thrombotic thrombocytopenic purpura.

Journal: Blood

Published: November 07, 2018

Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens.

Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens.

Journal: Blood advances

Published: May 05, 2017

Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura.

Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura.

Journal: Blood

Published: December 23, 2016

A single-center prospective study on the safety of plasma exchange procedures using a double-viral-inactivated and prion-reduced solvent/detergent fresh-frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy.

A single-center prospective study on the safety of plasma exchange procedures using a double-viral-inactivated and prion-reduced solvent/detergent fresh-frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy.

Journal: Transfusion

Published: June 23, 2016

Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy.

Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy.

Journal: AIDS (London, England)

Published: March 03, 2015

Showing 1-10 of 10

Last Updated: 09/26/2026